Skip to main content
NRX Pharmaceuticals, Inc. logo

NRX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · NRXP ISIN · US0894821034 LEI · 5493003FN4CLS0670T77 US Manufacturing
Filings indexed 456 across all filing types
Latest filing 2025-12-12 Regulatory Filings
Country US United States of America
Listing US NRXP

About NRX Pharmaceuticals, Inc.

https://www.nrxpharma.com/

NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system (CNS) disorders. The company focuses on addressing high unmet medical needs for patients with life-threatening conditions, particularly suicidal depression, suicidal bipolar depression, and post-traumatic stress disorder (PTSD). Its development pipeline is based on its N-methyl-D-aspartate (NMDA) receptor platform. The lead candidate, NRX-101, is an investigational oral medication for suicidal bipolar depression that has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration (FDA). Other key programs include NRX-100 for suicidal ideation and KETAFREE™, a preservative-free ketamine product.

Recent filings

Filing Released Lang Actions
FORM S-3/A
Regulatory Filings
2025-12-12 English
FORM 8-K
Regulatory Filings
2025-11-26 English
FORM 8-K/A
Regulatory Filings
2025-11-21 English
FORM 10-Q
Interim / Quarterly Report Q3 2025
2025-11-14 English
FORM 8-K
Regulatory Filings
2025-10-23 English
FORM 8-K
Regulatory Filings
2025-09-26 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.